FDA Finds no Link Between Asthma Drugs and Suicidal Behavior

In January 2009, the U.S. Food and Drug Administration (FDA) released a report on their investigation into patients taking asthma drugs and whether they were at increased risk to develop suicidal behavior.

The FDA’s 9-month review studied clinical trial data submitted by the manufacturers of three popular asthma drugs: Singulair, Accolate and Zyflo. The Singulair data noted that in over 9,900 patients treated with the drug, only one patient reported suicidal thoughts. AstraZeneca, the makers of Accolate, noted that only one patient in their control group of 7,540 patients attempted suicide. The study performed by the makers of Zyflo showed no patients reporting suicidal behaviors.

Despite the lack of data tying the use of asthma drugs with suicidal behaviors, in 2008 the makers of Singulair revised their list of possible side-effects to include depression, suicidality (suicidal thinking and behavior) and anxiousness.

Our medical malpractice lawyers are here to help you.

If you have been harmed by a health professional, please complete the form below for a free medical malpractice lawsuit review. A representative of our firm will be in touch shortly.

Click To Talk To Us Online

Please complete the following questionnaire:

Name
Email
Phone Number
Best time to call
City/State
What medical procedure were you having done?
How were you injured?
How did you hear about Weitz & Luxenberg?
Additional Comments

FDA Investigation Procedures

Law firm info: FDA discusses new violation investigaton procedures
New FDA procedures for drug, medical device development violations

Botulinum Toxin Warnings

Our lawyers provide info from the FDA about Botulinum safety warnings
FDA alert: Established names for Botulinum toxin drugs have changed

2008 Health Advisories

Read the FDA report about smoking cessation drug Chantix (Varenicline)
Important FDA report: Side-effects linked to Chantix (Varenicline)

Name

Phone

strictly confidential

Your Question